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Background
Treatment with Interleukin-1 (Il-1) receptor antagonist
(anakinra) has been reported to be effective in some
patients with systemic-onset juvenile idiopathic arthritis
(SoJIA).
Aim
To examine the safety and the efficacy of anakinra treat-
ment in a regional cohort of SoJIA patients.
Methods
We retrospectively reviewed the medical records of
patients with SoJIA treated with anakinra (1-3 mg/kg/
day) in our unit between December 2004 and july 2010.
Anakinra’s effects were studied on several parameters
including fever, rash, erythrocyte sedimentation rate, C-
reactive protein levels, arthritis joints count, assessment
of disease activity (by physician and parent/patient) and
pain (by parent/patient). Resulting data were analysed to
characterize therapies, clinical course and adverse
events.
Results
A total of 22 patients were included. Their mean age at
the onset of treatment was 8,6 (1,8-15,6) years; disease
duration was 2,4 (0-10,2) years. They had been follow
up for 11-56 months. Fever and rash were resolved in
18 patients (82%) within the first 3 months. Active
arthritis persisted at 3 months in 22% of patients, at 6
months in 14%, and at 12 months in 22%. Sixteen
patients (70%), including 6 patients receiving anakinra
as first-line therapy, attained a complete response. One
patient stopped anakinra due to severe skin reaction and
two patients due to infections: one severe pneumonia
and one positive intradermoreaction. We observed 10
episodes of macrophage activation syndrome in 9
patients (40%), 8 episodes were present at the SoJIA
diagnosis and 2 while receiving anakinra.
Conclusion
In our experience, first-line therapy with anakinra in
SoJIA patients was associated with an improved resolu-
tion of symptoms. These results justify further studies of
Il-1 inhibition as first-line therapy in SoJIA patients.
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